Navigation Links
Gentiva Reports Strong Second Quarter led by Home Health Segment
Date:7/31/2008

22,207 20,093

Payroll and related taxes 19,094 17,163

Deferred revenue 33,624 29,015

Medicare liabilities 8,782 7,985

Cost of claims incurred but not

reported 22,089 24,321

Obligations under insurance

programs 38,805 36,816

Other accrued expenses 34,138 42,282

Total current liabilities 178,739 179,979

Long-term debt 331,000 307,696

Deferred tax liabilities, net 57,152 48,572

Other liabilities 22,109 22,557

Shareholders' equity 353,375 323,429

Total liabilities and

shareholders' equity $942,375 $882,233

Common shares outstanding 28,507 28,046

(A) Cash, cash equivalents and restricted cash included restricted cash of $0.3 million at June 29, 2008 and $22.0 million at December 30, 2007.

(B) Short-term and long-term investments at June 29, 2008 and December 30, 2007 consisted of AAA-rated auction rate securities. At June 29, 2008, long-term investments were presented net of a $0.4 million valuation allowance, the charge for which was recorded in shareholders' equity.

(C) Accounts receivable, net, included an allowance for doubtful accounts of $10.5 million and $9.4 million at June 29, 2008 and December 30, 2007, respectively.

(in 000's) Six Months

Condensed Statements of Cash Flows 2008 2007

OPERATING ACTIVITIES:

Net income
'/>"/>

SOURCE Gentiva Health Services, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. United Therapeutics Reports Second Quarter 2008 Financial Results
2. The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future
3. Neurocrine Biosciences Reports Second Quarter 2008 Results
4. Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
5. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
6. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
7. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009
8. Cepheid Reports Second Quarter Revenue of $42.1 Million
9. Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009
10. Lilly Reports Solid Second-Quarter Results
11. Sangamo BioSciences Reports Second Quarter 2008 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...s., Nov. 19 Arlington Medical Reso...eading driver of antibiotic selection in nosocomia...gainst gram-positive and gram-negative pathogens. ...ocomial pneumonia, surveyed European physicians re...ide appropriate coverage against common pathogens,...
(Date:11/19/2009)...ynthesis Companies Form International Gene Synthes...in Risk Reduction ,Five Member Companies Represe... , (PRWEB) November 19, 2...hesis companies today announced agreement that the...e biosecurity in the gene synthesis industry. By ...
(Date:11/18/2009)...ndards and Technology (NIST) has demonstrated a re...and measuring elusive hazards such as concealed ex... pesticides distributed in soil by wind and rain. ...tional techniques for detecting traces of these ma...ng distinct electrically positive and negative end...
(Date:11/18/2009)...swire-FirstCall/ -- Sangamo BioSciences, Inc. (Nas...iversity of Pennsylvania investigator sponsored Ph...se (ZFN) based product, SB-728-T, for HIV/AIDS wer...nternet. ,, Data were presented in a student co...edicine from a single subject treated with SB-728-...
Breaking Biology Technology:Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4Prototype NIST method detects and measures elusive hazards 2Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS 2
... visit an Arts and Crafts exhibit at the Milwaukee... As my wife (and curator) was reading from the exh...on in the integration of technology, business, and...nchant for repeating itself. The late 1800s, when ... a time of unprecedented social and economic uphea...
...ed a public deployment of PV.Web for Oneida Count...raphic information systems) maps through the " Lan...ite. , ,Built on ESRI,s ArcIMS technology, anyone ...ery, and report on both spatial and non-spatial la...uilding addresses and outlines, zoning and land-us...
...day that Rockwood Clinic , a group practice sprea...ton area, has purchased a suite of their Centricit...hnologies the clinic is installing is GE,s Patient...ointments, update their patient profile and make c... active role in uploading and downloading health i...
Other Biology Technology:Shaping a grand design 2Shaping a grand design 3
(Date:11/20/2009)...in the November 2009 issue of the journal GENETIC...w a family of genes (1-aminocyclopropane-1-carboxy...roduction of ethylene. This gas affects many aspec... the foundation for future genetic manipulation th...rvive and thrive in difficult terrain, increase yi...
(Date:11/20/2009)...ribute their abstracts to the World Congress on Os...obal meeting devoted to all aspects of osteoporosi...e Congress will be held in Florence, Italy from Ma... submitted online at http://www.iofwco-ecceo10.or...0. , IOF and ESCEO are pleased to announce that ...
(Date:11/20/2009)...al-tar-based sealcoats in parking lots may be the ... USGS study. PAHs or polycyclic aromatic hydroca...tar deposits, and can have toxic effects. It,s lon...st; however, the specific sources of these PAHs ar...t from indoor areas near parking lots with coal-ta...
Breaking Biology News(10 mins):It's a gas: New discovery may lead to heartier, high-yielding plants 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3From toxic dust and algae to ill winds from Africa 2From toxic dust and algae to ill winds from Africa 3From toxic dust and algae to ill winds from Africa 4From toxic dust and algae to ill winds from Africa 5AMERIGROUP Foundation Honors Warehouse of Hope Founder Craig Parson as a Healthy Hero 53505 1AMERIGROUP Foundation Honors Warehouse of Hope Founder Craig Parson as a Healthy Hero 53505 2American Cancer Society Hope Lodges Sign 29th Contract to Implement SoftBrands Systems 53503 1American Cancer Society Hope Lodges Sign 29th Contract to Implement SoftBrands Systems 53503 2New Study Shows That Pharmacogenomics Could Benefit Patients Spur Investment in Innovation 53501 1New Study Shows That Pharmacogenomics Could Benefit Patients Spur Investment in Innovation 53501 2New Study Shows That Pharmacogenomics Could Benefit Patients Spur Investment in Innovation 53501 3
...9, 2008 A plot of land on the campus of Auburn Un...ng practices can produce similar cotton crops to t...J.F. Duggar at the Agricultural and Mechanical Col... experiment to test his theories that sustainable ... growers would use crop rotation and include winte...
...r fir is gaining popularity among American consume...rees. Consumers favor Fraser fir for its conical s...llent needle retention. , Consumer surveys indica...factor affecting Christmas tree selection, followe...onally, Americans have preferred dense trees, wher...
...ter is a fundamental need of all life on our plane...as become one of conflict and tension. Global wate...tions, while ecosystems are paying a severe price ...ke for our security and the health of the planet, ...the world,s expansive population? Two world-renown...
Other Biology News:Experiment demonstrates 110 years of sustainable agriculture 2Consumers influence christmas tree styles 2Experts to discuss global water crisis 2
Goat Anti-synphilin-1 (V-19) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Porcine IFN-gamma ELISpot Kit from R&D Systems
... the basic components required for the development...nant canine Monocyte Chemotactic Protein 1 (MCP-1)...ontains sufficient materials to run ELISAs on appr...e following conditions are met:2 1. For assayi...
Rat Anti-CCR5 Monoclonal Antibody, Unconjugated, Clone HEK / 1 / 85a from Abcam
Biology Products: